false
OasisLMS
zh-CN,en,fr,de,ja,es
Catalog
35th AM (2025) - Poster Session
Targeting Neuroinflammation in Alcohol Use Disorde ...
Targeting Neuroinflammation in Alcohol Use Disorder
Back to course
Pdf Summary
This review examines the potential of anti-inflammatory pharmacotherapies, particularly aspirin (ASA) and statins, as adjunct treatments for schizophrenia, highlighting the neuroinflammatory mechanisms implicated in its pathophysiology. While ASA and statins are commonly used for other medical conditions, their ability to reduce psychotic symptoms through inflammation modulation is under investigation. Several randomized controlled trials (RCTs) indicate potential benefits: aspirin adjunctive therapy has reduced schizophrenia symptoms in some studies, and statins like simvastatin, pravastatin, lovastatin, and atorvastatin have demonstrated variable effects on negative symptoms, inflammation, cognition, and lipid metabolism in schizophrenia patients.<br /><br />Separately, the review also summarizes RCTs assessing neuroinflammation-targeting drugs in Alcohol Use Disorder (AUD), including minocycline, ibudilast, and N-acetylcysteine (NAC). Minocycline, known for microglial dampening and effective in animal models, showed no clinical impact on cravings or inflammatory markers in heavy drinkers. Ibudilast, a PDE inhibitor and macrophage migration inhibitory factor modulator, yielded mixed results across trials—some noted reductions in craving, cue-reactivity, and heavy drinking especially among women and depressed patients, while others found no overall benefits on drinking or inflammation. NAC trials indicated a reduction in drinks per drinking day but no significant effects on heavy drinking days, abstinence, or mood symptoms.<br /><br />Overall, findings remain inconsistent, and the lack of changes in peripheral inflammatory markers challenges the understanding of central versus systemic treatment effects. Notably, subgroup analyses suggest benefits may depend on individual inflammatory profiles, advocating for stratified therapeutic approaches rather than broad application. The authors conducted a systematic literature review, analyzing dosages, efficacy, and side effects from English-language RCTs to inform these conclusions.<br /><br />In summary, anti-inflammatory adjuncts like ASA, statins, ibudilast, and NAC show promise but require further stratified research to clarify their role in treating schizophrenia and AUD by targeting neuroinflammation.
Keywords
anti-inflammatory pharmacotherapies
aspirin (ASA)
statins
schizophrenia
neuroinflammation
randomized controlled trials (RCTs)
Alcohol Use Disorder (AUD)
minocycline
ibudilast
N-acetylcysteine (NAC)
×